Exelixis, Inc. (EXEL)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS30161Q1040
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Exelixis, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 14:09. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 09 Feb 2027 16:00 | 1.03 | — | — | Upcoming |
| 29 Oct 2026 16:00 | 0.90 | 0.94 | +4.0% | Beat |
| 05 Aug 2026 16:00 | 0.86 | 0.91 | +5.9% | Beat |
| 05 May 2026 16:00 | 0.76 | 0.87 | +14.0% | Beat |
| 10 Feb 2026 16:00 | 0.81 | 0.94 | +16.2% | Beat |
| 04 Nov 2025 16:00 | 0.67 | 0.78 | +16.2% | Beat |
| 28 Jul 2025 16:00 | 0.65 | 0.75 | +16.2% | Beat |
| 13 May 2025 16:00 | 0.44 | 0.62 | +39.8% | Beat |
| 11 Feb 2025 16:00 | 0.49 | 0.55 | +11.8% | Beat |
| 29 Oct 2024 16:00 | 0.42 | 0.47 | +12.0% | Beat |
| 06 Aug 2024 16:00 | 0.37 | 0.84 | +129.9% | Beat |
| 30 Apr 2024 16:00 | 0.29 | 0.17 | -40.6% | Miss |
| 06 Feb 2024 16:00 | 0.31 | 0.33 | +6.8% | Beat |
| 01 Nov 2023 16:00 | 0.19 | 0.10 | -46.4% | Miss |
| 01 Aug 2023 16:00 | 0.22 | 0.31 | +40.3% | Beat |
| 09 May 2023 16:00 | 0.22 | 0.16 | -27.6% | Miss |
| 07 Feb 2023 16:00 | -0.05 | -0.03 | +42.9% | Beat |
| 01 Nov 2022 16:00 | 0.24 | 0.31 | +30.8% | Beat |
| 09 Aug 2022 16:00 | 0.24 | 0.28 | +14.6% | Beat |
| 10 May 2022 16:00 | 0.23 | 0.26 | +15.6% | Beat |
| 17 Feb 2022 16:00 | 0.16 | 0.35 | +125.0% | Beat |
| 02 Nov 2021 16:00 | 0.27 | 0.20 | -24.5% | Miss |
| 05 Aug 2021 16:00 | 0.14 | 0.37 | +166.7% | Beat |
| 06 May 2021 16:00 | 0.09 | 0.09 | 0.0% | In line |
| 10 Feb 2021 16:00 | 0.10 | 0.14 | +37.0% | Beat |
| 05 Nov 2020 16:00 | 0.04 | 0.04 | -6.4% | Miss |
| 06 Aug 2020 16:00 | 0.14 | 0.25 | +77.2% | Beat |
| 05 May 2020 16:00 | 0.17 | 0.19 | +10.1% | Beat |
| 25 Feb 2020 16:00 | 0.21 | 0.26 | +22.1% | Beat |
| 30 Oct 2019 16:00 | 0.22 | 0.34 | +51.6% | Beat |
| 31 Jul 2019 16:00 | 0.28 | 0.29 | +4.7% | Beat |
| 01 May 2019 16:00 | 0.24 | 0.24 | +2.1% | Beat |
| 12 Feb 2019 16:00 | 0.23 | 0.37 | +61.9% | Beat |
| 01 Nov 2018 16:00 | 0.17 | 0.41 | +141.2% | Beat |
| 01 Aug 2018 16:00 | 0.16 | 0.28 | +75.0% | Beat |
| 02 May 2018 16:00 | 0.15 | 0.37 | +146.7% | Beat |
| 26 Feb 2018 16:00 | 0.10 | 0.12 | +20.0% | Beat |
| 01 Nov 2017 16:00 | 0.07 | 0.26 | +288.6% | Beat |
| 02 Aug 2017 16:00 | 0.03 | 0.08 | +168.6% | Beat |
| 01 May 2017 16:00 | — | 0.05 | +1,260.1% | Beat |
| 27 Feb 2017 16:00 | -0.04 | 0.12 | +392.8% | Beat |
| 03 Nov 2016 16:00 | -0.12 | 0.01 | +108.0% | Beat |
| 03 Aug 2016 16:00 | -0.25 | -0.16 | +38.4% | Beat |
| 04 May 2016 16:00 | -0.21 | -0.27 | -27.8% | Miss |
| 29 Feb 2016 16:00 | -0.22 | -0.19 | +12.7% | Beat |
| 10 Nov 2015 16:00 | -0.16 | -0.22 | -35.8% | Miss |
| 11 Aug 2015 16:00 | -0.21 | -0.22 | -3.8% | Miss |
| 30 Apr 2015 16:00 | -0.24 | -0.18 | +25.0% | Beat |
| 24 Feb 2015 16:00 | -0.30 | -0.30 | +1.3% | Beat |
| 04 Nov 2014 16:00 | -0.35 | -0.30 | +15.1% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 2.3B | +7.0% | 782.6M | 33.7% | 2.78 | +58.0% | 844.3M |
| 2024 | 2.2B | +18.5% | 521.3M | 24.0% | 1.76 | +170.8% | 633.8M |
| 2023 | 1.8B | +13.6% | 207.8M | 11.4% | 0.65 | +16.1% | 170.4M |
| 2022 | 1.6B | — | 182.3M | 11.3% | 0.56 | — | 224.2M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 70.70 | 70.95 | 69.67 | 69.84 | -1.22% | 1,631,800 | |
| 11 Nov 2026 | 70.47 | 70.96 | 69.66 | 70.70 | +0.17% | 2,229,700 | |
| 10 Nov 2026 | 71.56 | 72.14 | 69.74 | 70.58 | -1.62% | 5,583,500 | |
| 09 Nov 2026 | 70.21 | 72.15 | 69.39 | 71.74 | +3.12% | 4,826,200 | |
| 06 Nov 2026 | 68.35 | 70.32 | 68.01 | 69.57 | +1.25% | 2,003,600 | |
| 05 Nov 2026 | 73.03 | 73.69 | 68.46 | 68.71 | -5.55% | 4,375,800 | |
| 04 Nov 2026 | 73.18 | 73.41 | 71.31 | 72.75 | +0.61% | 3,014,100 | |
| 03 Nov 2026 | 70.11 | 73.44 | 70.11 | 72.31 | +3.11% | 3,849,300 | |
| 02 Nov 2026 | 69.53 | 72.01 | 69.15 | 70.13 | +1.07% | 5,590,400 | |
| 30 Oct 2026 | 68.28 | 72.10 | 67.05 | 69.39 | +4.82% | 5,071,800 | |
| 1,249 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nears (opens in a new tab) MarketBeat · 11 Nov 2026 05:14
- Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript (opens in a new tab) SeekingAlpha · 10 Nov 2026 13:20
- Short Sellers Are Betting Against This Biotech Stock at All-Time Highs, But You Should Still Add it to Your Watchlist (opens in a new tab) Barchart · 09 Nov 2026 16:35
- Leerink Partners Maintains Market Perform on Exelixis, Raises Price Target to $58 (opens in a new tab) Benzinga · 05 Nov 2026 17:10
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November (opens in a new tab) 03 Nov 2026 21:05
- Exelixis (EXEL) International Revenue in Focus: Trends and Expectations (opens in a new tab) Zacks · 02 Nov 2026 13:15
- HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $78 (opens in a new tab) Benzinga · 02 Nov 2026 07:59
- Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL) (opens in a new tab) Simply Wall St. · 31 Oct 2026 12:08
- Exelixis (EXEL) Beats Q3 Estimates, Is The Stock Fully Priced? (opens in a new tab) Simply Wall St. · 31 Oct 2026 04:20
- EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales (opens in a new tab) Zacks · 30 Oct 2026 15:46
- Exelixis (EXEL) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 30 Oct 2026 15:00
- Exelixis, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 30 Oct 2026 12:30
- What Exelixis (EXEL) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 30 Oct 2026 00:14
- Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (opens in a new tab) Zacks · 29 Oct 2026 21:00
- Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates (opens in a new tab) Zacks · 29 Oct 2026 20:35
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 70.70 USD
- Market cap
- 17.0B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 23.3 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 16.7 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 20.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 13.1 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 0.0 / 10 |
|
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 20.91× | Fair | 30.56× |
| P/E (forward) | 16.34× | Fair | 14.16× |
| Price / book | 9.32× | Weak | 3.5× |
| Price / sales | 6.83× | Weak | 3.33× |
| EV / EBITDA | 15.81× | Weak | 11.19× |
| Free cash flow yield | 4.5% | Fair | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 96.3% | Good | 54.9% |
| Operating margin | 40.2% | Good | 5.8% |
| Net margin | 35.4% | Good | 1.2% |
| Return on equity | 44.3% | Good | 4.4% |
| Return on assets | 23.5% | Good | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 12.9% | Good | 10.1% |
| EPS growth / year | 70.6% | Good | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.09× | Good | 0.4× |
| Net debt / EBITDA | -0.71× | Good | 1.46× |
| Current ratio | 3.21× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow EXEL and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.